Therapeutic potential of metformin in normal glucose tolerant persons with metabolic syndrome

References

• Wilson PW, Meigs JB. Cardiometabolic risk: a Framingham perspective. Int J Obes. 2008;32(S2):S17–S20.
   Web of Science ®Google Scholar
• Lukacova-Zib I, Gopalakrishnan G. Therapeutic options for the prevention of type 2 diabetes mellitus in the metabolic syndrome. Mt Sinai J Med. 2010;77(5):524–532.
   PubMedGoogle Scholar
• Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9(1):9–48.
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234.
   PubMed Web of Science ®Google Scholar
• Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102(9):1014–1019.
   PubMed Web of Science ®Google Scholar
• Mogul HR, Peterson SG, Weinstein BI, et al. Metformin and carbohydrate-modified diet: a novel obesity treatment protocol. Preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia. Heart Disease. 2001;3:285–292.
   PubMedGoogle Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes. A patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• Boyle JG, Mokay GA, Fisher M. Drugs for diabetes: part 1 metformin. Br J Cardiol. 2010;17:231–234.
   Google Scholar
• Krsevska B, Dimitrovski C, Pemovska J, et al. Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsilinemic women with a polycystic ovary syndrome. Prilozi. 2006;27:57–66.
   PubMedGoogle Scholar
• Cheang KI, Huszar JM, Best AM, et al. Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Diab Vasc Dis Res. 2009;6(2):110–119.
   PubMed Web of Science ®Google Scholar
• Oppelt PG, Mueller A, Jentsch K, et al. The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2009;118(9):633–637.
   PubMed Web of Science ®Google Scholar
• Otta CF, Wior M, Iraci GS, et al. Clinical, metabolic and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized double-blind and placebo-control trial. Gynecol Endocrinol. 2010;26(3):173–178.
   PubMed Web of Science ®Google Scholar
• Saxena P, Prakash A, Nigam A. Effect of metformin therapy on 2-h post glucose insulin levels in patients of polycyctic ovarian syndrome. J Hum Reprod Sci. 2010;3(3):139–142.
   PubMedGoogle Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374(9702):1677–1686.
   PubMed Web of Science ®Google Scholar
• Fontbonne A, Diouf I, Baccara-Dinet M, et al. Effect of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose abnormalities: a post-hoc analysis of the BIGPRO 1 trial. Diabetes Metab. 2009;35(5):385–391.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Outcomes Study Research Group, Orchard TJ, Temprosa M, Barrett-Connor E, et al. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2013;30:46–55.
   PubMed Web of Science ®Google Scholar
• Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071–1094.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention: identification of subgroups that benefitted most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019;42 (4):601–608.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Prevention or delay of type 2 diabetes: standards of Medical Care in diabetes-2017. Diabetes Care. 2017;40(1):S44–S47.
   PubMedGoogle Scholar
• Vitale C, Mercuro G, Cornoldi A, et al. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med. 2005;258(3):250–256.
   PubMed Web of Science ®Google Scholar
• Lord J, Thomas R, Fox B, et al. The effect of metformin on fat distribution and metabolic syndrome in women wth polycystic ovary syndrome-a randomized, double-blind, placebo-controlled trial. BJOG: Int J Obstetrics Gynaecol. 2006;113(7):817–824.
   PubMed Web of Science ®Google Scholar
• de Aguiar LGK, Bahia LR, Villela N, et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care. 2006;29(5):1083–1089.
   PubMed Web of Science ®Google Scholar
• Harden KA, Cowan PA, Velasquez-Mieyer P, et al. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. J Amer Acad Nurse Pract. 2007;19(7):368–377.
   PubMed Web of Science ®Google Scholar
• Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial . J Pediatr Endocrinol Metab. 2008;21(4):339–348.
   PubMed Web of Science ®Google Scholar
• Andreadis EA, Katsanou PM, Georgiopoulos DX, et al. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects-the Carmos study. Exp Clin Endocrinol Diabetes. 2008;117(04):175–180.
   PubMed Web of Science ®Google Scholar
• Lima LM, Wiemsperger N, Kraemer-Aguiar LG, et al. Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen. Clinics (Sao Paolo). 2009;64:415–420.
   PubMed Web of Science ®Google Scholar
• Fitch K, Abbara S, Lee H, et al. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS. 2012;26(5):587–597.
   PubMed Web of Science ®Google Scholar
• Wong AKF, Symon R, AlZadjali MA, et al. The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail. 2012;14(11):1303–1310.
   PubMed Web of Science ®Google Scholar
• Kamenova P, Atanasova I, Kirilov G. Metformin reduces cardiometabolic risk factors in people at high risk for development of type 2 diabetes and cardiovascular disease. J Diabetes Metab. 2014;5:470.
   Google Scholar
• Kamenova P, Atanasova I, Kirilov G. Metformin improves insulin secretion and reduces insulin resistance in people at high risk for development of type 2 diabetes mellitus and cardiovascular disease. MRJMMS. 2016;4(3):152–161.
   Google Scholar
• Reaven GM, Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553,
   PubMed Web of Science ®Google Scholar
• Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16(5):442–443.
   PubMed Web of Science ®Google Scholar
• Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract. 2000;113:3–13.
   Google Scholar
• Moller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med. 1991;325(13):938.
   PubMed Web of Science ®Google Scholar
• Cabezas MC, van Wijk JPH, Elte JWF, et al. Effect of metformin on the regulation of free fatty acids in insulin resistance: a double-blind placebo-controlled study. J Nutr Metab. 2012;2012:394623. doi:10.1155/2012/394623.
   PubMedGoogle Scholar
• Mathews DR, Hasker JP, Rudenski AS, et al. Homeostasis model assessment of insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Duncan MH, Singh BM, Wise PH, et al. A simple measure of insulin resistance. Lancet. 1995;346(8967):120–121.
   PubMed Web of Science ®Google Scholar
• Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83(8):2694–2698.
   PubMed Web of Science ®Google Scholar
• Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–2410.
   PubMed Web of Science ®Google Scholar
• Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the clucose clamp technique in the assessment of insulin sensitivity. Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23(1):57–63.
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome- a new world wide definition. Lancet. 2005;366(9491):1059–1062.
   PubMed Web of Science ®Google Scholar
• Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007;56(4):1153–1159.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Knowler WC, Crandall JP, et al. Metformin for diabetes prevention: insights gained from the diabetes prevention program/diabetes prevention program outcomes study. Diabetologia. 2017;60(9):1601–1611.
   PubMed Web of Science ®Google Scholar
• Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323–332.,
   PubMed Web of Science ®Google Scholar